Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
Kathleen M MooreSetsuko K ChambersErika P HamiltonLee-May ChenAmit M OzaSharad A GhamandeGottfried E KonecnySteven C PlaxeDaniel L SpitzJill J J GeenenTiffany A Troso-SandovalJaniel M CragunEsteban Rodrigo ImedioSanjeev KumarGanesh M MugunduZhongwu LaiJuliann ChmieleckiSuzanne F JonesDavid R SpigelKaren A CadooPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Adavosertib showed preliminary efficacy when combined with chemotherapy. The most promising treatment combination was adavosertib 225 mg twice daily on days 1-3, 8-10, and 15-17 plus carboplatin every 21 days. However, hematologic toxicity was more frequent than would be expected for carboplatin monotherapy, and the combination requires further study to optimize the dose, schedule, and supportive medications.